The DOI matches its Crossref record; 162 of the 162 references it cites were found in a registry or an index.
The Ras-association domain family (RASSF) members and their role in human tumourigenesis
Open accessAbstract
Ras proteins play a direct causal role in human cancer with activating mutations in Ras occurring in approximately 30% of tumours. Ras effectors also contribute to cancer, as mutations occur in Ras effectors, notably B-Raf and PI3-K, and drugs blocking elements of these pathways are in clinical development. In 2000, a new Ras effector was identified, RAS-association domain family 1 (RASSF1), and expression of the RASSF1A isoform of this gene is silenced in tumours by methylation of its promoter. Since methylation is reversible and demethylating agents are currently being used in clinical trials, detection of RASSF1A silencing by promoter hypermethylation has potential clinical uses in cancer diagnosis, prognosis and treatment. RASSF1A belongs to a new family of RAS effectors, of which there are currently 8 members (RASSF1-8). RASSF1-6 each contain a variable N-terminal segment followed by a Ras-association (RA) domain of the Ral-GDS/AF6 type, and a specialised coiled-coil structure known as a SARAH domain extending to the C-terminus. RASSF7-8 contain an N-terminal RA domain and a variable C-terminus. Members of the RASSF family are thought to function as tumour suppressors by regulating the cell cycle and apoptosis. This review will summarise our current knowledge of each member of the RASSF family and in particular what role they play in tumourigenesis, with a special focus on RASSF1A, whose promoter methylation is one of the most frequent alterations found in human tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
Herman, J. G., Graff, J. R., Myöhänen, S., Nelkin, B. D., & Baylin, S. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9821 · Cited by 5,646
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Systematic functional analysis of the Caenorhabditis elegans genome using RNAi
Kamath, R. S., Fraser, A. G., Dong, Y., Poulin, G., Durbin, R., Gotta, M., Kanapin, A., Le Bot, N., Moreno, S., Sohrmann, M., et al. (2003) · Nature · doi:10.1038/nature01278 · Cited by 3,616
Gene Silencing in Cancer in Association with Promoter Hypermethylation
Herman, J. G., & Baylin, S. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023075 · Cited by 3,422
(1977) · PubMed · Cited by 1,801
Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions
Kölch, W. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3510289 · Cited by 1,441
Dammann, R., Li, C., Yoon, J.-H., Chin, P. L., Bates, S., & Pfeifer, G. P. (2000) · Nature Genetics · doi:10.1038/77083 · Cited by 1,064
Hulo, N. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj063 · Cited by 971
Full-genome RNAi profiling of early embryogenesis in Caenorhabditis elegans
Sönnichsen, B., Koski, L. B., Walsh, A., Marschall, P., Neumann, B., Brehm, M., Alleaume, A.-M., Artelt, J., Bettencourt, P., Cassin, E., et al. (2005) · Nature · doi:10.1038/nature03353 · Cited by 894
Substrate Specificities and Identification of Putative Substrates of ATM Kinase Family Members
Kim, S.-T., Lim, D.-S., Canman, C. E., & Kastan, M. B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.53.37538 · Cited by 810
Epigenetic Inactivation of RASSF1A in Lung and Breast Cancers and Malignant Phenotype Suppression
Burbee, D. G., Forgacs, E., Zochbauer-Muller, S., Shivakumar, L., Fong, K., Gao, B., Randle, D., Kondo, M., Virmani, A., Bader, S., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.9.691 · Cited by 769
Neoplastic Characteristics of the DNA Found in the Plasma of Cancer Patients
Stroun, M., Anker, P., Maurice, P., Lyautey, J., Lederrey, C., & Beljanski, M. (2009) · Oncology · doi:10.1159/000226740 · Cited by 733
Ubiquitous Activation of Ras and Jak/Stat Pathways in Human HCC
Calvisi, D. F., Ladu, S., Gorden, A., Farina, M., Conner, E. A., Lee, J., Factor, V. M., & Thorgeirsson, S. S. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.01.006 · Cited by 710
High levels of De Novo methylation and altered chromatin structure at CpG islands in cell lines
Antequera, F., Boyes, J., & Bird, A. (1990) · Cell · doi:10.1016/0092-8674(90)90015-7 · Cited by 699
Hubbard, T. J. P., Aken, B. L., Beal, K., Ballester, B., Caccamo, M., Chen, Y., Clarke, L., Coates, G., Cunningham, F., Cutts, T., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl996 · Cited by 636
Downward, J. (1998) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(98)80061-0 · Cited by 555
Lerman, M. I., & Minna, J. D. (2000) · PubMed · Cited by 538
Hypermethylation of CpG Islands in Primary and Metastatic Human Prostate Cancer
Yegnasubramanian, S., Kowalski, J., Gonzalgo, M. L., Zahurak, M., Piantadosi, S., Walsh, P. C., Bova, G. S., De Marzo, A. M., Isaacs, W. B., & Nelson, W. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3972 · Cited by 527
Microtubule-targeted anticancer agents and apoptosis
Bhalla, K. N. (2003) · Oncogene · doi:10.1038/sj.onc.1207233 · Cited by 461
Katagiri, K., Maeda, A., Shimonaka, M., & Kinashi, T. (2003) · Nature Immunology · doi:10.1038/ni950 · Cited by 461
Maruyama, R., Toyooka, S., Toyooka, K. O., Harada, K., Virmani, A. K., Zöchbauer‐Müller, S., Farinas, A. J., Vakar‐Lopez, F., Minna, J. D., Sagalowsky, A. I., et al. (2001) · PubMed · Cited by 422
Wistuba, I. I., Behrens, C., Virmani, A. K., Mele, G. M., Milchgrub, S., Girard, L., Fondon, J. W., Garner, H. R., McKay, B., Latif, F., et al. (2000) · PubMed · Cited by 405
The RASSF1A Tumor Suppressor Blocks Cell Cycle Progression and Inhibits Cyclin D1 Accumulation
Shivakumar, L., Minna, J., Sakamaki, T., Pestell, R., & White, M. A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.12.4309-4318.2002 · Cited by 393
Agathanggelou, A., Honorio, S., Macartney, D. P., Martinez, A., Dallol, A., Rader, J., Fullwood, P., Chauhan, A., Walker, R., Shaw, J. A., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204175 · Cited by 376
Identification of a Novel Ras-Regulated Proapoptotic Pathway
Khokhlatchev, A., Rabizadeh, S., Xavier, R., Nedwidek, M., Chen, T., Zhang, X.-F., Seed, B., & Avruch, J. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00683-8 · Cited by 357
The CpG island searcher: a new WWW resource.
Takai, D., & Jones, P. A. (2003) · PubMed · Cited by 354
PRASKOVA, M., KHOKLATCHEV, A., ORTIZ-VEGA, S., & AVRUCH, J. (2004) · Biochemical Journal · doi:10.1042/bj20040025 · Cited by 342
Hung, J. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520310056030 · Cited by 339
Deletions of the Short Arm of Chromosome 3 in Solid Tumors and the Search for Suppressor Genes
(1997) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60096-2 · Cited by 335
Wistuba, I. I., Behrens, C., Milchgrub, S., Bryant, D., Hung, J., Minna, J. D., & Gazdar, A. F. (1999) · Oncogene · doi:10.1038/sj.onc.1202349 · Cited by 329
Kang, G. H., Lee, S., Kim, W. H., Lee, H. W., Kim, J. C., Rhyu, M.-G., & Ro, J. Y. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64901-2 · Cited by 329
Maruyama, R., Toyooka, S., Toyooka, K. O., et al. (2002) · PubMed · Cited by 326
DNA methylation in serum of breast cancer patients: an independent prognostic marker.
Müller, H. M., Widschwendter, A., Fiegl, H., Ivarsson, L., Goebel, G., Perkmann, E., Marth, C., & Widschwendter, M. (2003) · PubMed · Cited by 317
Catto, J. W. F., Azzouzi, A.-R., Rehman, I., Feeley, K. M., Cross, S. S., Amira, N., Fromont, G., Sibony, M., Cussenot, O., Meuth, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.163 · Cited by 316
The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC–Cdc20 complex
Song, M. S., Song, S. J., Ayad, N. G., Chang, J. S., Lee, J. H., Hong, H. K., Lee, H., Choi, N., Kim, J., Kim, H., et al. (2004) · Nature Cell Biology · doi:10.1038/ncb1091 · Cited by 311
Dreijerink, K., Braga, E., Kuzmin, I., Geil, L., Duh, F.-M., Angeloni, D., Zbar, B., Lerman, M. I., Stanbridge, E. J., Minna, J. D., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.131216298 · Cited by 294
High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma.
Lo, K. W., Kwong, J., Hui, A. B., Chan, S. Y., To, K. F., Chan, A. S. Y., Chow, L. S. N., Teo, P., Johnson, P. J., & Huang, D. P. (2001) · PubMed · Cited by 290
Progress in understanding the molecular pathogenesis of human lung cancer
Sekido, Y., Fong, K. M., & Minna, J. D. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00010-9 · Cited by 290
Ras Uses the Novel Tumor Suppressor RASSF1 as an Effector to Mediate Apoptosis
Vos, M. D., Ellis, C. A., Bell, A., Birrer, M. J., & Clark, G. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000463200 · Cited by 289
de Caceres, I. I., Battagli, C., Esteller, M., Herman, J. G., Dulaimi, E., Edelson, M. I., Bergman, C., Ehya, H., Eisenberg, B. L., & Cairns, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1529 · Cited by 282
A Quantitative Promoter Methylation Profile of Prostate Cancer
Jerónimo, C., Henrique, R., Hoque, M. O., Mambo, E., Ribeiro, F. R., Varzim, G., Oliveira, J., Teixeira, M. R., Lopes, C., & Sidransky, D. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0894 · Cited by 260
Sundaresan, V., Ganly, P. S., Hasleton, P. S., Rudd, R., Sinha, G., Bleehen, N. M., & Rabbitts, P. H. (1993) · Lung Cancer · doi:10.1016/0169-5002(93)90371-4 · Cited by 257
Fiegl, H., Millinger, S., Mueller-Holzner, E., Marth, C., Ensinger, C., Berger, A., Klocker, H., Goebel, G., & Widschwendter, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2438 · Cited by 252
DNA methylation profiles of lung tumors.
Toyooka, S., Toyooka, K. O., Maruyama, R., Virmani, A. K., Girard, L., Miyajima, K., Harada, K., Ariyoshi, Y., Takahashi, T., Sugio, K., et al. (2001) · PubMed · Cited by 243
Hoon, D. S. B., Spugnardi, M., Kuo, C., Huang, S. K., Morton, D. L., & Taback, B. (2004) · Oncogene · doi:10.1038/sj.onc.1207505 · Cited by 241
De novo methylation of the MyoD1 CpG island during the establishment of immortal cell lines.
Jones, P. A., Wolkowicz, M. J., Rideout, W. M., Gonzales, F. A., Marziasz, C. M., Coetzee, G. A., & Tapscott, S. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.16.6117 · Cited by 234
Tumor Suppressor Gene Promoter Hypermethylation in Serum of Breast Cancer Patients
Dulaimi, E., Hillinck, J., de Caceres, I. I., Al-Saleem, T., & Cairns, P. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0597 · Cited by 232
Katagiri, K., Imamura, M., & Kinashi, T. (2006) · Nature Immunology · doi:10.1038/ni1374 · Cited by 230
Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines
Harada, K., Toyooka, S., Maitra, A., Maruyama, R., Toyooka, K. O., Timmons, C. F., Tomlinson, G. E., Mastrangelo, D., Hay, R. J., Minna, J. D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205446 · Cited by 226
Quantitative Assessment of Promoter Hypermethylation during Breast Cancer Development
Lehmann, U., Länger, F., Feist, H., Glöckner, S., Hasemeier, B., & Kreipe, H. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64880-8 · Cited by 222
Anzalone, A. A., Lettini, L., Fonsatti, E., & Maio, M. (2005) · The Women s Oncology Review · doi:10.1080/14733400500093346 · Cited by 221
The Role of RASSF1A Methylation in Cancer
Hesson, L. B., Cooper, W. N., & Latif, F. (2007) · Disease Markers · doi:10.1155/2007/291538 · Cited by 218
Gene Promoter Methylation in Plasma and Sputum Increases with Lung Cancer Risk
Belinsky, S. A., Klinge, D. M., Dekker, J. D., Smith, M. W., Bocklage, T. J., Gilliland, F. D., Crowell, R. E., Karp, D. D., Stidley, C. A., & Picchi, M. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0625 · Cited by 215
Tumor Susceptibility of Rassf1a Knockout Mice
Tommasi, S., Dammann, R., Zhang, Z., Wang, Y., Liu, L., Tsark, W. M., Wilczynski, S. P., Li, J., You, M., & Pfeifer, G. P. (2005) · Cancer Research · doi:10.1158/0008-5472.92.65.1 · Cited by 214
The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle.
Denko, N. C., Giaccia, A. J., Stringer, J. R., & Stambrook, P. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.5124 · Cited by 209
Ortiz-Vega, S., Khokhlatchev, A., Nedwidek, M., Zhang, X.-F., Dammann, R., Pfeifer, G. P., & Avruch, J. (2002) · Oncogene · doi:10.1038/sj.onc.1205192 · Cited by 209
Identification of Nore1 as a Potential Ras Effector
Vavvas, D., Li, X., Avruch, J., & Zhang, X.-F. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.10.5439 · Cited by 208
Involvement of Ras Activation in Human Breast Cancer Cell Signaling, Invasion, and Anoikis
Eckert, L. B., Repasky, G. A., Ülkü, A. S., McFall, A., Zhou, H., Sartor, C. I., & Der, C. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0396 · Cited by 207
A novel family ofras-binding domains
Ponting, C. P., & Benjamin, D. R. (1996) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(96)30038-8 · Cited by 205
RASSF1A Is Part of a Complex Similar to the Drosophila Hippo/Salvador/Lats Tumor-Suppressor Network
Guo, C., Tommasi, S., Liu, L., Yee, J.-K., Dammann, R., & Pfeifer, G. P. (2007) · Current Biology · doi:10.1016/j.cub.2007.02.055 · Cited by 200
The tumor suppressor RASSF1A in human carcinogenesis: an update.
Dammann, R., Schagdarsurengin, U., Seidel, C., Strunnikova, M., Rastetter, M., Baier, K., & Pfeifer, G. P. (2005) · PubMed · doi:10.14670/hh-20.645 · Cited by 197
Crucial functions of the Rap1 effector molecule RAPL in lymphocyte and dendritic cell trafficking
Katagiri, K., Ohnishi, N., Kabashima, K., Iyoda, T., Takeda, N., Shinkai, Y., Inaba, K., & Kinashi, T. (2004) · Nature Immunology · doi:10.1038/ni1111 · Cited by 197
Mitotic checkpoints: from yeast to cancer
Wassmann, K., & Benezra, R. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00161-1 · Cited by 195
Control of microtubule stability by the RASSF1A tumor suppressor
Liu, L., Tommasi, S., Lee, D.-H., Dammann, R., & Pfeifer, G. P. (2003) · Oncogene · doi:10.1038/sj.onc.1206984 · Cited by 193
Detection of Bladder Cancer in Urine by a Tumor Suppressor Gene Hypermethylation Panel
Dulaimi, E., Uzzo, R. G., Greenberg, R. E., Al-Saleem, T., & Cairns, P. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0127 · Cited by 188
Protein Kinase C: Seeing two domains
Newton, A. C. (1995) · Current Biology · doi:10.1016/s0960-9822(95)00191-6 · Cited by 187
Baksh, S., Tommasi, S., Fenton, S., Yu, V. C., Martins, L. M., Pfeifer, G. P., Latif, F., Downward, J., & Neel, B. G. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.05.010 · Cited by 186
The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway
Saavedra, H. I., Knauf, J. A., Shirokawa, J. M., Wang, J., Ouyang, B., Elisei, R., Stambrook, P. J., & Fagin, J. A. (2000) · Oncogene · doi:10.1038/sj.onc.1203723 · Cited by 186
RASSF2 Is a Novel K-Ras-specific Effector and Potential Tumor Suppressor
Vos, M. D., Ellis, C. A., Elam, C., Ülkü, A. S., Taylor, B. J., & Clark, G. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300554200 · Cited by 183
Promoter Hypermethylation in Benign Breast Epithelium in Relation to Predicted Breast Cancer Risk
Lewis, C. M., Cler, L. R., Bu, D.-W., Zöchbauer‐Müller, S., Milchgrub, S., Naftalis, E. Z., Leitch, A. M., Minna, J. D., & Euhus, D. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.166.11.1 · Cited by 182
K-ras mutations and RASSF1A promoter methylation in colorectal cancer
van Engeland, M., Roemen, G. M., Brink, M., Pachen, M. M., Weijenberg, M. P., de Bruïne, A. P., Arends, J.-W., van den Brandt, P. A., FPM de Goeij, A., & Herman, J. G. (2002) · Oncogene · doi:10.1038/sj.onc.1205466 · Cited by 181
Recognizing and Defining True Ras Binding Domains I: Biochemical Analysis
Wohlgemuth, S., Kiel, C., Krämer, A., Serrano, L., Wittinghofer, F., & Herrmann, C. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.02.048 · Cited by 177
Ji, L., Nishizaki, M., Gao, B., Burbee, D. G., Kondo, M., Kamibayashi, C., Xu, K., Yen, N., Atkinson, E. N., Fang, B., et al. (2002) · PubMed · Cited by 176
Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma
Dammann, R., Schagdarsurengin, U., Liu, L., Otto, N., Gimm, O., Dralle, H., Boehm, B. O., Pfeifer, G. P., & Hoang-Vu, C. (2003) · Oncogene · doi:10.1038/sj.onc.1206582 · Cited by 173
Detection of Breast Cancer in Nipple Aspirate Fluid by CpG Island Hypermethylation
Krassenstein, R., Sauter, E., Dulaimi, E., Battagli, C., Ehya, H., Klein-Szanto, A., & Cairns, P. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0410-3 · Cited by 171
Microtubule dynamics and tubulin interacting proteins
Walczak, C. E. (2000) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)00056-3 · Cited by 169
Vos, M. D., Martinez, A., Elam, C., Dallol, A., Taylor, B. J., Latif, F., & Clark, G. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0339 · Cited by 159
Kuzmin, I., Gillespie, J. W., Protopopov, A. I., Geil, L., Dreijerink, K. M. A., Yang, Y., Vocke, C. D., Duh, F.-M. C., Zabarovsky, E. R., Minna, J. D., et al. (2002) · PubMed · Cited by 158
The Drosophila RASSF Homolog Antagonizes the Hippo Pathway
Polesello, C., Huelsmann, S., Brown, N. H., & Tapon, N. (2006) · Current Biology · doi:10.1016/j.cub.2006.10.060 · Cited by 151
Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin, U., Gimm, O., Hoang‐Vu, C., Dralle, H., Pfeifer, G. P., & Dammann, R. (2002) · PubMed · Cited by 149
The Ras Effector RASSF2 Is a Novel Tumor-Suppressor Gene in Human Colorectal Cancer
Akino, K., Toyota, M., Suzuki, H., Mita, H., Sasaki, Y., Ohe-Toyota, M., Issa, J. J., Hinoda, Y., Imai, K., & Tokino, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.051 · Cited by 148
RASSF6 is a novel member of the RASSF family of tumor suppressors
Allen, N. P. C., Donninger, H., Vos, M. D., Eckfeld, K., Hesson, L. B., Gordon, L. E., Birrer, M. J., Latif, F., & Clark, G. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210440 · Cited by 146
Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers
Zöchbauer‐Müller, S., Lam, S. C., Toyooka, S., Virmani, A. K., Toyooka, K. O., Seidl, S., Minna, J. D., & Gazdar, A. F. (2003) · International Journal of Cancer · doi:10.1002/ijc.11458 · Cited by 146
Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas
REIFENBERGER, J., Knobbe-Thomsen, C. B., Sterzinger, A. A., Blaschke, B., Schulte, K. W., Ruzicka, T., & Reifenberger, G. (2004) · International Journal of Cancer · doi:10.1002/ijc.11722 · Cited by 146
RASSF1A Interacts with Microtubule-Associated Proteins and Modulates Microtubule Dynamics
Dallol, A., Agathanggelou, A., Fenton, S. L., Ahmed-Choudhury, J., Hesson, L. B., Vos, M. D., Clark, G., Downward, J., Maher, E. R., & Latif, F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0267 · Cited by 146
The RASSF1A Tumor Suppressor Activates Bax via MOAP-1
Vos, M. D., Dallol, A., Eckfeld, K., Allen, N. P. C., Donninger, H., Hesson, L. B., Calvisi, D. F., Latif, F., & Clark, G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m512128200 · Cited by 143
Xing, M., Cohen, Y., Mambo, E., Tallini, G., Udelsman, R., Ladenson, P. W., & Sidransky, D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3242 · Cited by 143
Mehrotra, J., Vali, M., McVeigh, M., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0118 · Cited by 143
Dammann, R., Schagdarsurengin, U., Strunnikova, M., Rastetter, M., Seidel, C., Liu, L., Tommasi, S., & Pfeifer, G. P. (2003) · PubMed · doi:10.14670/hh-18.665 · Cited by 139
Byun, D.-S., Lee, M., Chae, K. S., Ryu, B. G., & Chi, S. G. (2001) · PubMed · Cited by 138
RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours
Astuti, D., Agathanggelou, A., Honorio, S., Dallol, A., Martinsson, T., Kogner, P., Cummins, C., Neumann, H. P. H., Voutilainen, R., Dahia, P. L. M., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204968 · Cited by 137
Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
Lee, M., Kim, H. Y., Byun, D.-S., Lee, S., Lee, C. H., Kim, J. I., Chang, S., & Chi, S. G. (2001) · PubMed · Cited by 134
Zhang, Y., Ahsan, H., Chen, Y., Lunn, R. M., Wang, L., Chen, S., Lee, P., Chen, C., & Santella, R. M. (2002) · Molecular Carcinogenesis · doi:10.1002/mc.10076 · Cited by 133
Kim, D.-H., Kim, J. S., Ji, Y., Shim, Y. M., Kim, H., Han, J., & Park, J. (2003) · PubMed · Cited by 131
NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers
Hesson, L. B., Dallol, A., Minna, J. D., Maher, E. R., & Latif, F. (2003) · Oncogene · doi:10.1038/sj.onc.1206191 · Cited by 130
Hesson, L. B., Bièche, I., Krex, D., Crinière, E., Hoang‐Xuan, K., Maher, E. R., & Latif, F. (2004) · Oncogene · doi:10.1038/sj.onc.1207407 · Cited by 128
Hwang, E., Ryu, K., Pääkkönen, K., Güntert, P., Cheong, H., Lim, D., Lee, J., Jeon, Y. H., & Cheong, C. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610716104 · Cited by 127
The Pro-apoptotic Ras Effector Nore1 May Serve as a Ras-regulated Tumor Suppressor in the Lung
Vos, M. D., Martínez, A., Ellis, C. A., Vallecorsa, T., & Clark, G. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211019200 · Cited by 125
A novel inter action motif, SARAH, connects three classes of tumor suppressor
Scheel, H., & Hofmann, K. (2003) · Current Biology · doi:10.1016/j.cub.2003.11.007 · Cited by 124
Methylated DNA collected by tampons: a new tool to detect endometrial cancer.
Fiegl, H., Gattringer, C., Widschwendter, A., Schneitter, A., Ramoni, A., Sarlay, D., Gaugg, I., Goebel, G., Müller, H. M., Mueller-Holzner, E., et al. (2004) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.882.13.5 · Cited by 123
RASSF4/AD037 Is a Potential Ras Effector/Tumor Suppressor of the RASSF Family
Eckfeld, K., Hesson, L. B., Vos, M. D., Bièche, I., Latif, F., & Clark, G. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2065 · Cited by 120
Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients.
Battagli, C., Uzzo, R. G., Dulaimi, E., de Cáceres, I. I., Krassenstein, R., Al‐Saleem, T., Greenberg, R. E., & Cairns, P. (2003) · PubMed · Cited by 120
Tommasi, S., Dammann, R., Jin, S., Zhang, X., Avruch, J., & Pfeifer, G. P. (2002) · Oncogene · doi:10.1038/sj.onc.1205365 · Cited by 115
Chen, J., Lui, W., Vos, M. D., Clark, G. J., Takahashi, M., Schoumans, J., Khoo, S. K., Petillo, D., Lavery, T. T., Sugimura, J., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00269-1 · Cited by 114
RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors
Nakamura, N., Carney, J. A., Jin, L. G., Kajita, S., Pallarés, J., Zhang, H., Qian, X., Sebo, T. J., Erickson, L. A., & Lloyd, R. V. (2005) · Laboratory Investigation · doi:10.1038/labinvest.3700306 · Cited by 111
Honorio, S., Agathanggelou, A., Schuermann, M., Pankow, W., Viacava, P., Maher, E. R., & Latif, F. (2003) · Oncogene · doi:10.1038/sj.onc.1206057 · Cited by 111
Armesilla, A. L., Williams, J. C., Buch, M. H., Pickard, A., Emerson, M., Cartwright, E. J., Oceandy, D., Vos, M. D., Gillies, S., Clark, G. J., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m307557200 · Cited by 111
Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma
Morris, M. R., Hesson, L. B., Wagner, K. J., Morgan, N. V., Astuti, D., Lees, R. D., Cooper, W. N., Lee, J., Gentle, D., MacDonald, F., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206914 · Cited by 108
Debeer, P., Schoenmakers, E. F. P. M., Twal, W. O., Argraves, W. S., Smet, L. D., Fryns, J.-P., & de Ven, W. J. M. V. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.2.98 · Cited by 105
RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma
Chow, L. S., Lo, K. W., Kwong, J., To, K., Tsang, K., Lam, C., Dammann, R., & Huang, D. P. (2004) · International Journal of Cancer · doi:10.1002/ijc.20079 · Cited by 103
Kiel, C., Wohlgemuth, S., Rousseau, F., Schymkowitz, J. W. H., Ferkinghoff‐Borg, J., Wittinghofer, F., & Serrano, L. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.02.046 · Cited by 102
Chan, M. W. Y., Chan, L. W., Tang, N. L. S., Lo, K. W., TONG, J. H. M., Chan, A. W. H., Cheung, H. Y., Wong, W. S., Chan, P. S. F., Lai, F. M., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.10971 · Cited by 102
Liu, L., Broaddus, R. R., Yao, J. C., Xie, S.-S., White, J. A., Wu, T., Hamilton, S. R., & Rashid, A. (2005) · Modern Pathology · doi:10.1038/modpathol.3800490 · Cited by 102
Rong, R., Jin, W., Zhang, J., Sheikh, M. S., & Huang, Y. K. (2004) · Oncogene · doi:10.1038/sj.onc.1207901 · Cited by 102
The RASSF1A Isoform of RASSF1 Promotes Microtubule Stability and Suppresses Tumorigenesis
van der Weyden, L., Tachibana, K.-E. K., Gonzalez, M., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.18.8356-8367.2005 · Cited by 99
Epigenetic inactivation of RASSF1A in head and neck cancer.
Dong, S. M., Sun, D., Benoit, N. E., et al. (2003) · PubMed · Cited by 98
Rong, R., Jiang, L., Sheikh, M. S., & Huang, Y. K. (2007) · Oncogene · doi:10.1038/sj.onc.1210575 · Cited by 96
Nore1 inhibits tumor cell growth independent of Ras or the MST1/2 kinases
Aoyama, Y., Avruch, J., & Zhang, X. (2004) · Oncogene · doi:10.1038/sj.onc.1207486 · Cited by 94
Wang, J., Lee, J. J., Wang, L., Liu, D. D., Lu, C., Fan, Y.-H., Hong, W. K., & Mao, L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0652 · Cited by 94
Rabizadeh, S., Xavier, R. J., Ishiguro, K., Bernabé-Ortiz, J. C., Lopez-Ilasaca, M. A., Khokhlatchev, A. V., Mollahan, P., Pfeifer, G. P., Avruch, J., & Seed, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401699200 · Cited by 93
Yates, D. R., Rehman, I., Meuth, M., Cross, S. S., Hamdy, F. C., & Catto, J. W. F. (2005) · Oncogene · doi:10.1038/sj.onc.1209209 · Cited by 90
Involvement of the RASSF1A Tumor Suppressor Gene in Controlling Cell Migration
Dallol, A., Agathanggelou, A., Tommasi, S., Pfeifer, G. P., Maher, E. R., & Latif, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0247 · Cited by 89
Nore1 and RASSF1 Regulation of Cell Proliferation and of the MST1/2 Kinases
Avruch, J., Praskova, M. D., Ortiz-Vega, S., Liu, M., & Zhang, X. (2006) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)07025-4 · Cited by 86
RASSF1A Suppresses the c-Jun-NH2-Kinase Pathway and Inhibits Cell Cycle Progression
Whang, Y. M., Kim, Y. H., Kim, J. S., & Yoo, Y. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2792 · Cited by 82
Ikeda, M., Hirabayashi, S., Fujiwara, N., et al. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.02.013 · Cited by 81
Fujita, H., Fukuhara, S., Sakurai, A., Yamagishi, A., Kamioka, Y., Nakaoka, Y., Masuda, M., & Mochizuki, N. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409701200 · Cited by 76
Release of RASSF1C from the nucleus by Daxx degradation links DNA damage and SAPK/JNK activation
Kitagawa, D., Kajiho, H., Negishi, T., Ura, S., Watanabe‐Asaka, T., Wada, T., Ichijo, H., Katada, T., & Nishina, H. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601212 · Cited by 74
Methylation Assay for the Diagnosis of Lung Cancer on Bronchial Aspirates: A Cohort Study
Schmiemann, V., Böcking, A., Kazimirek, M., Onofre, A. S. C., Gabbert, H. E., Kappes, R., Gerharz, C. D., & Grote, H. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0999 · Cited by 73
The relationship between aberrant methylation and survival in non-small-cell lung cancers
Toyooka, S., Suzuki, M., Maruyama, R., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602013 · Cited by 71
Ras-Induced Transformation and Signaling Pathway
Yamamoto, T., Taya, S., & Kaibuchi, K. (1999) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a022519 · Cited by 71
Yu, M., TONG, J. H. M., Chan, P. K. S., Lee, T., Chan, M. W. Y., Chan, A. W. H., Lo, K. W., & To, K. (2003) · International Journal of Cancer · doi:10.1002/ijc.11051 · Cited by 71
Song, M. S., Chang, J. S., Song, S. J., Yang, T. H., Lee, H., & Lim, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409115200 · Cited by 68
RASSF1A gene inactivation in non‐small cell lung cancer and its clinical implication
Endoh, H., Yatabe, Y., Shimizu, S., Tajima, K., Kuwano, H., Takahashi, T., & Mitsudomi, T. (2003) · International Journal of Cancer · doi:10.1002/ijc.11184 · Cited by 65
Quantitative evaluation of RASSF1Amethylation in the non-lesional, regenerative and neoplastic liver
Gioia, S. D., Bianchi, P. P., Destro, A., Grizzi, F., Malesci, A., Laghi, L., Levrero, M., Morabito, A., & Roncalli, M. G. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-89 · Cited by 65
Zhang, C., Li, Z., Cheng, Y., Jia, F., Li, R., Wu, M.-C., Li, K., & Wei, L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2268 · Cited by 64
Wang, Y., Yu, Z., Wang, T., et al. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2006.12.007 · Cited by 64
Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma
Li, J., El‐Naggar, A. K., & Mao, L. (2005) · Cancer · doi:10.1002/cncr.21215 · Cited by 63
Kuzmin, I., Liu, L., Dammann, R., Geil, L., Stanbridge, E. J., Wilczynski, S. P., Lerman, M. I., & Pfeifer, G. P. (2003) · PubMed · Cited by 62
Haplotype mapping of the bronchiolitis susceptibility locus near IL8
Hull, J., Rowlands, K., Lockhart, E., Sharland, M., Moore, C. E., Hanchard, N. A., & Kwiatkowski, D. P. (2004) · Human Genetics · doi:10.1007/s00439-003-1038-x · Cited by 61
Liu, L., Vo, A., & McKeehan, W. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3896 · Cited by 61
Carcinogen Exposure and Epigenetic Silencing in Bladder Cancer
Marsit, C. J., Karagas, M. R., Schned, A. R., & Kelsey, K. T. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1371.031 · Cited by 60
Irimia, M., Fraga, M. F., Sánchez‐Céspedes, M., & Esteller, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207914 · Cited by 58
Kim, D.-H., Kim, J. S., Park, J., Lee, S. K., Ji, Y., Kwon, Y. M., Shim, Y. M., Han, J., & Park, J. (2003) · PubMed · Cited by 57
Identification of RASSF8 as a candidate lung tumor suppressor gene
Falvella, F. S., Manenti, G., Spinola, M., Pignatiello, C., Conti, B., Pastorino, U., & Dragani, T. A. (2006) · Oncogene · doi:10.1038/sj.onc.1209422 · Cited by 57
Qian, Z. R., Sano, T., Yoshimoto, K., Yamada, S., Ishizuka, A., Mizusawa, N., Horiguchi, H., Hirokawa, M., & Asa, S. L. (2005) · Laboratory Investigation · doi:10.1038/labinvest.3700248 · Cited by 57
Kinashi, T., & Katagiri, K. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02214.x · Cited by 56
Estrabaud, E., Lassot, I., Blot, G., Rouzic, E. L., Tanchou, V., Quéméneur, É., Daviet, L., Margottin-Goguet, F., & Bénarous, R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2530 · Cited by 56
Moshnikova, A., Frye, J., Shay, J. W., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511837200 · Cited by 55
Gene expression profiles in human cells submitted to genotoxic stress
Sakamoto‐Hojo, E. T., Mello, S. S., Pereira, E. C., Fachin, A. L., Cardoso, R. S., Junta, C. M., Sandrin‐Garcia, P., Donadi, E. A., & Passos, G. A. S. (2003) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2003.07.004 · Cited by 55
Ubiquitous Aberrant RASSF1A Promoter Methylation in Childhood Neoplasia
Wong, I. H. N., Chan, J., Wong, J. Y. P., & Tam, P. K. H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0378-3 · Cited by 53
Aberrant methylation of RASSF4/AD037 in nasopharyngeal carcinoma
Chow, L. S.-N., Lo, K. W., Kwong, J., Wong, A. Y.-H., & Huang, D. P. (2004) · Oncology Reports · doi:10.3892/or.12.4.781 · Cited by 45
Diep, C. B., Teixeira, M. R., Thorstensen, L., Wiig, J. N., Eknæs, M., Nesland, J. M., Giercksky, K.-E., Johansson, B., & Lothe, R. A. (2004) · Molecular Cancer · doi:10.1186/1476-4598-3-6 · Cited by 44
Park, H., Kang, H. C., Kim, I., Jang, S., Kim, K., Yoon, H., Jeong, S., & Park, J. (2006) · International Journal of Cancer · doi:10.1002/ijc.22276 · Cited by 43
Bitko, V., Garmon, N. E., Cao, T., Estrada, B., Oakes, J. E., Lausch, R. N., & Barik, S. (2004) · BMC Microbiology · doi:10.1186/1471-2180-4-28 · Cited by 42
Ras association domain family 1C protein stimulates human lung cancer cell proliferation
Amaar, Y. G., Minera, M., Hatran, L. K., Strong, D. D., Mohan, S., & Reeves, M. E. (2006) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00072.2006 · Cited by 41
Smith, A. J. H., Xian, J., Richardson, M., Johnstone, K. A., & Rabbitts, P. H. (2002) · Oncogene · doi:10.1038/sj.onc.1205530 · Cited by 39
Liu, L., Baier, K., Dammann, R., & Pfeifer, G. P. (2007) · Cell Cycle · doi:10.4161/cc.6.13.4435 · Cited by 34
RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer
Pijnenborg, J. M. A., Veen, G. C. D.-D., Kisters, N., Delvoux, B., van Engeland, M., Herman, J. G., & Groothuis, P. G. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl455 · Cited by 33
Linking tumor suppression, DNA damage and the anaphase-promoting complex
Jackson, P. K. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2004.05.005 · Cited by 30
Choi, N., Son, D., Song, I.-S., Lee, H., Lim, Y., Song, M. S., Lim, D., Lee, J., Kim, H., & Kim, J. (2005) · International Journal of Cancer · doi:10.1002/ijc.20916 · Cited by 20
Reuther, G. W., Buss, J. E., Quilliam, L. A., Clark, G. J., & Der, C. J. (2000) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(00)27288-1 · Cited by 19
Nore1B regulates TCR signaling via Ras and Carma1
Ishiguro, K., Avruch, J., Landry, A. L., Qin, S., Ando, T., Goto, H., & Xavier, R. J. (2006) · Cellular Signalling · doi:10.1016/j.cellsig.2006.01.015 · Cited by 14
Cited by
Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival
Drosten, M., Dhawahir, A., Sum, E. Y. M., Urosevic, J., Lechuga, C. G., Esteban, L. M., Castellano, E., Guerra, C., Santos, E., & Barbacid, M. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.7 · Cited by 347
Fold change and p-value cutoffs significantly alter microarray interpretations
Dalman, M. R., Deeter, A., Nimishakavi, G., & Duan, Z.-H. (2012) · BMC Bioinformatics · doi:10.1186/1471-2105-13-s2-s11 · Cited by 332
The RASSF proteins in cancer; from epigenetic silencing to functional characterization
Richter, A. M., Pfeifer, G. P., & Dammann, R. H. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.03.004 · Cited by 295
Vaissière, T., Hung, R. J., Zaridze, D., Moukeria, A., Cuenin, C., Fasolo, V., Ferro, G., Paliwal, A., Hainaut, P., Brennan, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2489 · Cited by 258
Alveolar rhabdomyosarcoma–associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression
Crose, L. E. S., Galindo, K. A., Kephart, J. G., Chen, C., Fitamant, J., Bardeesy, N., Bentley, R. C., Galindo, R. L., Ashley Chi, J.-T., & Linardic, C. M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67087 · Cited by 124
Metadata
- Authors
- van der Weyden, L., & Adams, D. J.
- Venue
- Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Publisher
- Elsevier BV
- Published
- 2007-09
- Volume
- 1776
- Issue
- 1
- Pages
- 58-85
- ISSN
- 0304-419X (ISSN-L)
- OpenAlex
- W2050474151
- Cited by
- 284
- References
- 162
- FWCI
- 6.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.